FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
Cancer Network,
The FDA has granted accelerated approval to vusolimogene oderparepvec-wtpg (RP1; Tudriqev) in combination with nivolumab (Opdivo…
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
UBM Medica,
The FDA has approved RP1 plus nivolumab for adults with advanced melanoma who progressed on anti–PD-1 therapy.
FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma
Cancer Network,
The FDA’s Cellular, Tissue, and Gene Therapies Adivosry Committee (CTGTAC) voted 10 to 3 that the benefit-risk profile of…
FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma
UBM Medica,
The FDA's CTGTAC voted 10-3 in favor RP1 plus nivolumab's benefit-risk profile in anti–PD-1–resistant advanced melanoma.